Pasireotide‐induced hyperglycemia in a patient with Cushing's disease: Potential use of sodium‐glucose cotransporter 2 inhibitor and glucagon‐like peptide‐1 receptor agonist for treatment
oleh: Masato Shikata, Kenji Ashida, Yuka Goto, Ayako Nagayama, Shimpei Iwata, Mamiko Yano, Nao Hasuzawa, Kento Hara, Kazutoshi Mawatari, Kiyohiko Sakata, Munehisa Tsuruta, Nobuhiko Wada, Masatoshi Nomura
| Format: | Article |
|---|---|
| Diterbitkan: | Wiley 2020-12-01 |
Deskripsi
Abstract Pasireotide improves hypercortisolemia and induces hyperglycemia via somatostatin receptor type‐5 stimulation. GLP‐1RA and SGLT2 inhibitor potentially help regulate hyperglycemia in patients with Cushing's disease, especially after pasireotide administration.